Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) changes shares on Friday trading session, with a change of 2.87% or $0.15 shares. The trading starts at $5.23 and closed at $5.22 throughout the day. The trading session low price was $5.16 and day high was $5.50 on Friday, June 19. After the session, the Healthcare sector daily volume shifted to 62389.0 while its average volume is 88.64K. In other hand, the GLMD market cap reached to $110.41M. While, its current target price is $5.37 according to WSJ.
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 11.64% and down -11.68% for month. Its quarterly performance was 50.00% above, while its half year performance is down -1.47%. GLMD yearly performance stood at negative -17.38% and fall -7.09% for year-to-date. Current recommendation for Galmed Pharmaceuticals Ltd. is 1.90.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. GLMD EPS (TTM) for 12-month is -1.09. EPS for this year is -78.30%, while for the next year its value is -1.51. Its EPS Q/Q reached -73.10%. It has an EPS of -1.90% down for past five years and for the next five years will be up 20.00%.
Let’s take a look on the analyst recommendations on GLMD for the current month and previous month. For the current month, 6 of 8 analysts recommend stock as Buy while 0 as Sell, 1 as overweight, 0 as underweight and 1 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $8.00-$33.00. Average target price for GLMD was reached at $20.50.
BVF Inc., Nantahala Capital Management, LLC and Ibex Investors LLC are the top three holders in Galmed Pharmaceuticals Ltd. (GLMD) stock. On Mar 30, 2020, BVF Inc. has 1.83 million shares which valued 6.34 million. On Mar 30, 2020, Nantahala Capital Management, LLC owned 1.3 million shares which valued at 4.51 million. On Mar 30, 2020, Ibex Investors LLC has a total of 0.96 million shares which valued at 3.34 million. In the end, Ibex Investors LLC have 4.56% shares outstanding of Galmed Pharmaceuticals Ltd. (GLMD) on Mar 30, 2020. The insider ownership moved to 21.36% and institutional holding shifted to 35.20%.
The company posted an EPS (TTM) of -1.09. According to the most recent quarter report on (Jun 2020), 8 analysts estimated an average EPS of -0.31, while -0.2 EPS posted a year ago period. Analyst Estimated EPS for GLMD published in the report was -0.42–0.26 during the same period. Comparing with last year, the average estimated EPS was -0.2 which is higher than -0.29 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for GLMD rise 9.46% for period of 200 days. SMA for 50 days was 12.79% which is showing green signal, while SMA-20 was 4.91%. The moving average value for Galmed Pharmaceuticals Ltd. (GLMD) is 5.12 and 5.00 for 200 and 50 days respectively.